Isoproscaline or 4-isopropoxy-3,5-dimethoxyphenethylamine is an analog of mescaline. It is closely related to proscaline and was first synthesized by David E. Nichols. It produces hallucinogenic, psychedelic, and entheogenic effects.
2,5-Dimethoxy-4-nitroamphetamine (DON) is a psychedelic drug and amphetamine. It is an analog of DOM and DOB. It is also closely related to 2C-N.
Ganesha (2,5-dimethoxy-3,4-dimethylamphetamine) is a lesser-known psychedelic drug. It is also a substituted amphetamine. It was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 24–32 mg. The drug is usually taken orally, although other routes such as rectally may also be used. Ganesha is synthesized from 2,5-dimethoxy-3,4-dimethylbenzaldehyde. Ganesha is the amphetamine analog of 2C-G. It is a particularly long lasting drug, with the duration listed in PiHKAL as being 18–24 hours, which might make it undesirable to some users. It is named after the Hindu deity, Ganesha. Very little is known about the dangers or toxicity of ganesha. Effects of ganesha include:
2C-T-15 or 2,5-dimethoxy-4-(β-cyclopropylthio)phenethylamine is a psychedelic phenethylamine of the 2C family. It was presumably first synthesized by Alexander Shulgin and reported in his book PiHKAL .
2C-T-17 or 2,5-dimethoxy-4-(β-secbutylthio)phenethylamine is a psychedelic phenethylamine of the 2C family. It was presumably first synthesized by Alexander Shulgin and reported in his book PiHKAL .
3,4-Methylenedioxy-N-methoxyamphetamine is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N-methoxy analogue of MDA. MDMEO was first synthesized by Alexander Shulgin. In his book PiHKAL , the minimum dosage is listed as 180 mg. MDMEO may be found as white crystals. It produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDMEO.
MDMEOET, or 3,4-methylenedioxy-N-methoxyethylamphetamine, is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N-methoxyethyl analogue of MDA. MDMEOET was first synthesized by Alexander Shulgin. In his book PiHKAL , the minimum dosage is listed as 180 mg. MDMEOET produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDMEOET.
3,4-Methylenedioxy-N-methylphentermine is a lesser-known psychedelic drug. MDMP was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 110 mg, and the duration is listed as approximately 6 hours. MDMP produces few to no effects, and is slightly similar to MDMA. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDMP.
3,4-Methylenedioxyphentermine (MDPH) is a lesser-known psychedelic drug. MDPH was first synthesized by Alexander Shulgin. In his book PiHKAL , the dosage range is listed as 160–240 mg, and the duration as 3–5 hours. MDPH's effects are very similar to those of MDA: they both are smooth and "stoning," and do not cause any visuals. They also alter dreams and dream patterns. Shulgin describes MDPH as a promoter; it promotes the effects of other drugs, similarly to 2C-D. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPH.
3,4-Methylenedioxy-N-propargylamphetamine (MDPL) is a lesser-known psychedelic drug and a substituted amphetamine. MDPL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 150 mg, and the duration unknown. MDPL causes few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPL.
3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine is an entactogen, psychedelic, and stimulant of the phenethylamine and amphetamine chemical classes. It is the N-hydroxy homologue of MDMA ("Ecstasy"), and the N-methyl homologue of MDOH. MDHMA was first synthesized and assayed by Alexander Shulgin. In his book PiHKAL, Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 4–8 hours. He describes MDHMA as causing entactogenic and open MDMA-like effects, easing communication, and increasing appreciation of the senses.
BOB (4-bromo-2,5,beta-trimethoxyphenethylamine) is a lesser-known psychedelic drug. It is the beta-methoxy analog of 2C-B. BOB was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 10–20 mg, and the duration listed as 10–20 hours. BOB produces an altered state of consciousness, tinnitus, a pleasant tingling throughout the body, and a sense of awareness. Very little data exists about the pharmacological properties, metabolism, and toxicity of BOB.
BOD (4-methyl-2,5,β-trimethoxyphenethylamine) is a lesser-known psychedelic drug. It is the beta-methoxy analog of 2C-D and was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 15–25 mg with a duration of 8–16 hours. Its reported effects include mild open-eye and moderate closed-eye alterations in visual perception, enhancement of conversation and sense of humor, and unpleasant physical effects such as nausea and lethargy. Very little data exists about the pharmacological properties, metabolism, and toxicity of BOD.
BOM (3,4,5,beta-tetramethoxyphenethylamine) is a lesser-known psychedelic drug. It is the beta-methoxy derivative of mescaline. BOM was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 200 mg, and the duration unknown. BOM produces few to no effects. Very little data exists about its pharmacological properties, metabolism, and toxicity.
2,5-Dimethoxy-4-methylphenylcyclopropylamine (DMCPA) is a lesser-known psychedelic drug and a substituted amphetamine. DMCPA was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 15–20 mg and the duration is listed as 4–8 hours. DMCPA produces open-eye visuals, anorexia, and psychedelic dreams. Shulgin gives it a +++ on the Shulgin Rating Scale.
IDNNA (2,5-dimethoxy-4-iodo-N,N-dimethylamphetamine) is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N,N-dimethyl analog of DOI. IDNNA was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 2.6 mg, and the duration unknown. IDNNA produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of IDNNA.
MDHOET, or 3,4-methylenedioxy-N-hydroxyethylamphetamine, is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N-hydroxyethyl analogue of MDA. MDHOET was first synthesized by Alexander Shulgin. In his book PiHKAL , the minimum dosage is listed as 50 mg. MDHOET produces few to no effects. Very little data exists about the pharmacology, pharmacokinetics, effects, and toxicity of MDHOET.
N-Ethyl-1,3-benzodioxolylpentanamine is a psychoactive drug and member of the phenethylamine chemical class which acts as an entactogen, psychedelic, and stimulant. It is the N-ethyl analog of 1,3-benzodioxolylpentanamine. Ethyl-K was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 40 mg and the duration is unknown. Very little is known about the pharmacology, pharmacokinetics, effects, and toxicity of Ethyl-K.
Methylenedioxyallylamphetamine is a lesser-known psychedelic drug. It is also the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 180 mg, and the duration unknown. MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.
Methylenedioxybenzylamphetamine, abbreviated MDBZ, and systematically named 3,4-methylenedioxy-N-benzylamphetamine, is a psychedelic drug. It is the N-benzyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL , the minimum dosage is listed as 150 mg, and the duration unknown. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.
